BE897397A - Preparation pharmaceutique - Google Patents
Preparation pharmaceutique Download PDFInfo
- Publication number
- BE897397A BE897397A BE0/211250A BE211250A BE897397A BE 897397 A BE897397 A BE 897397A BE 0/211250 A BE0/211250 A BE 0/211250A BE 211250 A BE211250 A BE 211250A BE 897397 A BE897397 A BE 897397A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- dds
- leprosy
- brodimoprim
- pharmaceutical preparation
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 10
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims abstract description 21
- BFCRRLMMHNLSCP-UHFFFAOYSA-N brodimoprim Chemical compound COC1=C(Br)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 BFCRRLMMHNLSCP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 206010024229 Leprosy Diseases 0.000 claims abstract description 10
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960000252 brodimoprim Drugs 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 241001147830 Mycobacterium lufu Species 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4600/82A CH651473A5 (de) | 1982-07-29 | 1982-07-29 | Pharmazeutisches praeparat. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE897397A true BE897397A (fr) | 1984-01-30 |
Family
ID=4279115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/211250A BE897397A (fr) | 1982-07-29 | 1983-07-28 | Preparation pharmaceutique |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5933218A (de) |
| BE (1) | BE897397A (de) |
| CH (1) | CH651473A5 (de) |
| DE (1) | DE3326165A1 (de) |
| FR (1) | FR2531861B1 (de) |
| GB (1) | GB2125293B (de) |
| IT (1) | IT1171692B (de) |
| NL (1) | NL194535C (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK387687A (da) * | 1986-07-28 | 1988-01-29 | Warner Lambert Co | Fremstilling af farmaceutisk praeparat til behandling af infektioner med mycobacterium avium-intracellulare komplekset |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE419444B (sv) * | 1973-11-08 | 1981-08-03 | Hoffmann La Roche | Forfarande for framstellning av nya 2,4-diamino-5-bensylpyrimidinderivat |
| ZW10681A1 (en) * | 1980-06-26 | 1982-02-24 | Hoffmann La Roche | Antibacterial agents |
| GB2082063A (en) * | 1980-08-15 | 1982-03-03 | Haughey Edward | Antibacterial drug |
-
1982
- 1982-07-29 CH CH4600/82A patent/CH651473A5/de not_active IP Right Cessation
-
1983
- 1983-07-15 IT IT22089/83A patent/IT1171692B/it active
- 1983-07-19 NL NL8302579A patent/NL194535C/nl not_active IP Right Cessation
- 1983-07-20 DE DE19833326165 patent/DE3326165A1/de active Granted
- 1983-07-21 FR FR8312071A patent/FR2531861B1/fr not_active Expired
- 1983-07-26 JP JP58135265A patent/JPS5933218A/ja active Granted
- 1983-07-28 BE BE0/211250A patent/BE897397A/fr not_active IP Right Cessation
- 1983-07-28 GB GB08320438A patent/GB2125293B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE3326165C2 (de) | 1993-07-22 |
| GB2125293A (en) | 1984-03-07 |
| DE3326165A1 (de) | 1984-04-12 |
| JPH0419968B2 (de) | 1992-03-31 |
| GB8320438D0 (en) | 1983-09-01 |
| IT1171692B (it) | 1987-06-10 |
| NL8302579A (nl) | 1984-02-16 |
| JPS5933218A (ja) | 1984-02-23 |
| NL194535C (nl) | 2002-07-02 |
| FR2531861B1 (fr) | 1987-08-28 |
| NL194535B (nl) | 2002-03-01 |
| FR2531861A1 (fr) | 1984-02-24 |
| CH651473A5 (de) | 1985-09-30 |
| GB2125293B (en) | 1985-11-13 |
| IT8322089A0 (it) | 1983-07-15 |
| IT8322089A1 (it) | 1985-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dobell et al. | On the cultivation of Entamoeba histolytica and some other entozoic amoebae | |
| EP0604631B1 (de) | Verwendung von Bakterienhüllen der Ordnung Beggiatoales oder der Gattung Vitreoscilla als aktiven Bestandteil eines Medikamentes zur Stimulierung der unspezifischen Immunität | |
| Mackaness et al. | The bactericidal action of isoniazid, streptomycin, and terramycin on extracellular and intracellular tubercle bacilli | |
| Dubos et al. | Differential Characteristics in vitro and in vivo of Several Substrains of BCG: I. Multiplication and Survival in vitro | |
| EP0065513A1 (de) | Antimykotische synergitische arzneimittelzusammensetzungen und verfahren zu deren herstellung. | |
| JPH06510547A (ja) | 抗アルコール活性を有し、エネルギー代謝と胃粘膜の酸を生成し分泌する機能とを刺激し、放射能防御活性と抗コレラ活性を有する医薬組成物 | |
| Miller | Folic Acid and Biotin Synthesis by Sulfonamide-sensitive and Sulfonamide-resistant Strains of Escherichia coli. | |
| FR2628324A1 (fr) | Compositions pharmaceutiques antivirales et immunostimulantes et procede pour les preparer | |
| WO1999055336A1 (fr) | Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson | |
| Walker et al. | The chemotherapeutics of the chaulmoogric acid series and other fatty acids in leprosy and tuberculosis: i. backtericidal action; active principle; specificity | |
| EP0217794A1 (de) | Verfahren zur behandlung der wirkung von alkohol | |
| FR2487195A1 (fr) | Procede et composition permettant d'abaisser le taux de cholesterol contenu dans le sang | |
| FR2574089A1 (fr) | Procede de production d'acides gras, en particulier d'acide g-linoleique a partir de tetrahymena, produits obtenus et preparation medicamenteuse ou alimentaire contenant de l'acide g-linolenique ou ses derives en tant qu'agent anti-agregation plaquettaire | |
| FR2531861A1 (fr) | Preparation pharmaceutique synergique a base de dds et de brodimoprim, pour le traitement de la lepre | |
| US4399130A (en) | Use of metallic salts of pyridine-2-thione-N-oxide to treat or prevent swine exudative epidermitis | |
| BE1030299B1 (fr) | Application de la 5'-méthylthioadénosine dans la préparation de médicaments ou de produits de santé anti-obésité | |
| FR2663539A1 (fr) | Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age. | |
| FR2472389A1 (fr) | Compositions antibiotiques contenant un macrolide et un aminoheteroside | |
| EP0137514A2 (de) | Verbindungen und Zusammensetzungen verwendbar bei der Prävention und Behandlung von Obesitas | |
| Pope | Growth inhibition of tubercle bacilli by analogues of biotin | |
| EP1389120B1 (de) | Verwendung von Nystatin zur Behandlung von Atherosklerose, welche mit der Präsenz von parasitären Pilzen einhergeht | |
| EP3930741A1 (de) | Verwendung von zyklischen destruxin-pilzpeptiden als antibakterielle wirkstoffe gegen clostridium perfringens | |
| BE505709A (de) | ||
| RU2699795C1 (ru) | Средство для лечения эймериозов у животных | |
| BE628615A (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: F. *HOFFMANN-LA ROCHE A.G. Effective date: 20020731 |